| 1 |
Antitranscriptional intermediary family-1? antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine |
|
| | Alaina J. Kessler, Andrew Para, George W. Niedt, Paula Klein | | | JAAD Case Reports. 2023; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Management of Cancer-Associated Myositis |
|
| | Albert Selva-O’Callaghan, Ernesto Trallero-Araguás, Javier Ros, Albert Gil-Vila, Julia Lostes, Antonia Agustí, Judit Riera-Arnau, Marcelo Alvarado-Cárdenas, Iago Pinal-Fernandez | | | Current Treatment Options in Rheumatology. 2022; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Capecitabine-induced activation of actinic keratosis: A common but underrecognized adverse event |
|
| | Samantha Marley, Shelly Stepenaskie, Naiara S. Barbosa | | | Current Problems in Cancer: Case Reports. 2021; 3: 100050 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Dermatomyositis induced by the secretion of Phyllomedusa bicolor or Kambô frog - A case report |
|
| | Mariana de la Vega, Gilberto Maldonado, Arnoldo Kraus | | | Toxicon. 2020; 184: 57 | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management |
|
| | SudhirChandra Sarangi, Pranav Sopory, SoumyaSucharita Pattnaik, KH Reeta | | | Indian Journal of Pharmacology. 2020; 52(5): 402 | | | [Pubmed] [Google Scholar] [DOI] | |
|
